Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with/without prior co-administration of rifampicin: A 144-week prospective study

BMC Infectious Diseases

Volumn 8, Issue , 2008, Pages

  Manosuthi, Weerawat ^a,b   Tantanathip, Preecha ^a   Prasithisirikul, Wisit ^a   Likanonsakul, Sirirat ^a   Sungkanuparph, Somnuek ^b  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; ITRACONAZOLE; LAMIVUDINE; NEVIRAPINE; PYRAZINAMIDE; RIFAMPICIN; RNA; STAVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA;

ADULT; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; RASH; TUBERCULOSIS; ANTIVIRAL RESISTANCE; BLOOD; DRUG COMBINATION; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIDDLE AGED; PROSPECTIVE STUDY; THAILAND; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; NEVIRAPINE; PROSPECTIVE STUDIES; RIFAMPIN; RNA, VIRAL; STAVUDINE; THAILAND; TREATMENT OUTCOME; TUBERCULOSIS; VIRAL LOAD;

EID: 55649110066     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-8-136     Document Type: Article

References (23)

1. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents U. S. Department of Health and Human Services (DHHS) 2008 http://AIDSinfo.nih.gov.
2. Renaud-Thery F Nguimfack BD Vitoria M Lee E Graaff P Samb B Perriens J Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens Aids 2007, 21(Suppl 4):S89-95. 10.1097/01.aids.0000279711.54922.f0 17620758
3. Lawn SD Myer L Bekker LG Wood R Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: Impact on treatment outcomes and implications for tuberculosis control Aids 2006, 20(12):1605-1612. 10.1097/01.aids.0000238406.93249.cd 16868441
4. Manosuthi W Chottanapand S Thongyen S Chaovavanich A Sungkanuparph S Survival rate and risk faptors of mortality among HIV/ tuberculosis-coinfected patients with and without antiretroviral therapy J Acquir Immune Defic Syndr 2006, 43(1):42-46. 10.1097/ 01.qai.0000230521.86964.86 16885778
5. Cohen K van Cutsem G Boulle A McIlleron H Goemaere E Smith PJ Maartens G Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis J Antimicrob Chemother 2008, 61(2):389-393. 10.1093/jac/dkm484 18096560
6. van Oosterhout JJ Kumwenda JJ Beadsworth M Mateyu G Longwe T Burger DM Zijlstra EE Nevirapine- ased antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians Antivir Ther 2007, 12(4):515-521. 17668560
7. Dean GL Back DJ de Ruiter A Effect of tuberculosis therapy on nevirapine trough plasma concentrations Aids 1999, 13(17):2489-2490. 10.1097/ 00002030-199912030-00029 10597799
8. Ribera E Pou L Lopez RM Crespo M Falco V Ocana I Ruiz I Pahissa A Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis J Acquir Immune Defic Syndr 2001, 28(5):450-453. 11744833
9. Oliva J Moreno S Sanz J Ribera E Molina JA Rubio R Casas E Marino A Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis Aids 2003, 17(4):637-638. 10.1097/ 00002030-200303070-00024 12598789
10. Autar RS Wit FW Sankote J Mahanontharit A Anekthananon T Mootsikapun P Sujaikaew K Cooper DA Lange JM Phanuphak P et al. Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis Antivir Ther 2005, 10(8):937-943. 16430199
11. Manosuthi W Mankatitham W Lueangniyomkul A Chimsuntorn S Sungkanuparph S Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin HIV Med 2008, 9(5):294-299. 10.1111/j.1468-1293.2008.00563.x 18400076
12. Manosuthi W Sungkanuparph S Thakkinstian A Rattanasiri S Chaovavanich A Prasithsirikul W Likanonsakul S Ruxrungtham K Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin Clin Infect Dis 2006, 43(2):253-255. 10.1086/505210 16779754
13. Veen J Raviglione M Rieder HL Migliori GB Graf P Grzemska M Zalesky R Standardized tuberculosis treatment outcome monitoring in Europe. Recommendations of a Working Group of the World Health Organization (WHO) and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform reporting by cohort analysis of treatment outcome in tuberculosis patients Eur Respir J 1998, 12(2):505-510. 10.1183/09031936.98.12020505 9727811
14. Launay O Roudiere L Boukli N Dupont B Prevoteau du Clary F Patey O David F Lortholary O Devidas A Piketty C et al. Assessment of cetirizine, an antihistamine, to prevent cutaneous reactions to nevirapine therapy: results of the viramune-zyrtec double-blind, placebo-controlled trial Clin Infect Dis 2004, 38(8):e66-72. 10.1086/382677 15095233
15. Tashima K Staszewski S Nelson M Rachlis A Skiest D Stryker R Bessen L Overfield S Ruiz N Wirtz V Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection Aids 2008, 22(2):275-279. 18097230
16. Reliquet V Allavena C Francois-Brunet C Perre P Bellein V Garre M May T Souala F Besnier JM Ratfi F Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study HIV Med 2006, 7(7):431-436. 10.1111/j.1468-1293.2006.00402.x 16925728
17. de Beaudrap P Etard JF Gueye FN Gueye M Landman R Girard PM Sow PS Ndoye I Delaporte E Long-Term Efficacy and Tolerance of Efavirenz- and Nevirapine-Containing Regimens in Adult HIV Type 1 Senegalese Patients AIDS Res Hum Retroviruses 2008, 18507521.
18. Manosuthi W Ruxrungtham K Likanonsakul S Prasithsirikul W Inthong Y Phoorisri T Sungkanuparph S Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis Clin Infect Dis 2007, 44(1):141-144. 10.1086/510078 17143831
19. McComsey G Lonergan JT Mitochondrial dysfunction: Patient monitoring and toxicity management J Acquir Immune Defic Syndr 2004, 37(Suppl 1):S30-35. 15319667
20. Vella S Giuliano M Dally LG Agresti MG Tomino C Floridia M Chiesi A Fragola V Moroni M et al. Piazza d Long-term follow-up of zidovudine therapy in asymptomatic HIV infection: Results of a multicenter cohort study. The Italian Zidovudine Evaluation Group J Acquir Immune Defic Syndr 1994, 7(1):31-38. 7903380
21. Scaling up Antiretroviral Therapy in Resource-limited Settings: Treatment Guidelines for a public Health Approach Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO) 2006 revision
22. Penzak SR Kabuye G Mugyenyi P Mbamanya F Natarajan V Alfaro RM Kityo C Formentini E Masur H Cy ochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda HIV Med 2007, 8(2):86-91. 10.1111/j.1468-1293.2007.00432.x 17352764
23. Wyen C Hendra H Vogel M Hoffmann C Knechten H Brockmeyer NH Bogner JR Rockstroh J Esser S Jaeger H et al. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients J Antimicrob Chemother 2008, 61(4):914-918. 10.1093/jac/dkn029 18281305